Free radicals, antioxidants and diabetes: Embryopathy, retinopathy, neuropathy, nephropathy and cardiovascular complications

Neuroembryology and Aging

Volumn 4, Issue 3, 2007, Pages 117-137

  Aruoma, Okezie I ^a   Neergheen, Vidushi S ^b   Bahorun, Theeshan ^b   Jen, Ling Sun ^c  

^a TOURO COLLEGE   (United States)

^b UNIVERSITY OF MAURITIUS   (Mauritius)

^c CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Antioxidants; Cardiovascular complications; Cognitive decline; Complementary medicine; Degenerative diseases; Diabetes; Flavonoids; Free radicals; Metabolic syndrome

Indexed keywords

ALKALOID; ANTIOXIDANT; APIGENIN; AZADIRACHTA INDICA EXTRACT; BUTEIN; CATECHIN; CHRYSIN; DAIDZEIN; DAIDZIN; EPICATECHIN; FLAVONOID; FREE RADICAL; GARLIC EXTRACT; GENISTEIN; GENISTIN; GINKGO BILOBA EXTRACT; HESPERETIN; LUTEOLIN; METFORMIN; MOMORDICA CHARANTIA EXTRACT; NARINGENIN; OCIMUM SANCTUM EXTRACT; PLANT EXTRACT; POLYPHENOL; PROANTHOCYANIDIN; REACTIVE OXYGEN METABOLITE; TAXIFOLIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASODILATOR AGENT;

ALTERNATIVE MEDICINE; ANGIOGENESIS; BLINDNESS; BLOOD RETINA BARRIER; BLOOD VESSEL OCCLUSION; BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; CONGENITAL HEART MALFORMATION; DEGENERATIVE DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA DAMAGE; DNA MODIFICATION; EMBRYO DEVELOPMENT; EMBRYOPATHY; ENDOTHELIUM CELL; GENE MUTATION; GENE REARRANGEMENT; GLYCATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY ANOMALY; KIDNEY DISEASE; LIPID PEROXIDATION; MACROPHAGE; MATERNAL DIABETES MELLITUS; MEDICAL RESEARCH; MEDICINAL PLANT; MESANGIUM CELL; METABOLIC DISORDER; METABOLIC SYNDROME X; MOLECULAR INTERACTION; MONOCYTE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONPHOTOCHEMICAL QUENCHING; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR AFFINITY; RETINA; RETINA BLOOD FLOW; RETINOPATHY; REVIEW; SMOOTH MUSCLE FIBER; VITREOUS BODY;

EID: 35649012656     PISSN: 16613406     EISSN: 16613414     Source Type: Journal    
DOI: 10.1159/000109344     Document Type: Review

References (231)

1. Gillham B, Papachristodoulou DK, Thomas JH: Will's Biochemical Basis of Medicine, ed 3. Oxford, Butterworth Heinemann, 1997.
2. Movassat J, Saulnier C, Serradas P, Portha B: Impaired development of pancreatic beta-cell mass is a primary event during the progression to diabetes in the GK rat. Diabetologia 1997;40:916-925.
3. Movassat J, Saulnier C, Portha B: Beta-cell mass depletion precedes the onset of hyperglycaemia in the GK rat, a genetic model of non-insulin-dependent diabetes mellitus. Diabetes Metab 1995;21:365-370.
4. Vinik A, Pittenger G, Rafaeloff R, Rosenberg L, Duguid W: Determinants of pancreatic islet cell mass: a balance between neogenesis and senescence/apoptosis. Diabetes Rev 1996;4:235-263.
5. Howard CF Jr, Van Bueren A: Changes in islet cell composition during development of diabetes in Macaca nigra. Diabetes 1986;35:165-171.
6. Howard CF Jr: Longitudinal studies on the development of diabetes in individual Macaca nigra. Diabetologia 1986;29:301-306.
7. De Koning EJ, Bodkin NL, Hansen BC, Clark A: Diabetes mellitus in Macaca mulatto monkeys is characterized by islet amyloidosis and reduction in beta-cell population. Diabetologia 1993;36:378-384.
8. Monnier VM, Glomb M, Elgawish A, Sell DR: The mechanism of collagen cross-linking in diabetes. A puzzle near resolution. Diabetes 1996;45(suppl 3):S67-S72.
9. Kwon G, Corbett JA, Rodi CP, Sullivan P, McDaniel ML: Interleukin-I beta-induced nitric oxide synthase expression by rat pancreatic beta-cells: evidence for the involvement of nuclear factor kappa B in the signaling mechanism. Endocrinology 1995;136:4790-4795.
10. Rabinovitch A, Suarez PW: Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 1998;55:1139-1149.
11. Ceriello A, Quatrato A, Giugliano D: Diabetes mellitus and hypertension: the possible role of hyperglycemia through oxidative stress. Diabetologia 1993;36:265-266.
12. Sato Y, Hotta N, Sakamoto N, Matsuoka S, Ohishi N, Yagi K: Lipid peroxide level in plasma of diabetic patients. Biochem Med 1979;21:104-107.
13. Jain SK: Hyperglycemia can cause membrane lipid peroxidation and osmotic fragility in human red blood cells. J Biol Chem 1989;264:21340-21345.
14. Halliwell B, Gutteridge JMC: Free Radicals in Biology and Medicine, ed 2. Oxford, Clarendon Press, 1989.
15. Babior BM, Woodman RC: Chronic granulomatous disease. Semin Hematol 1990;27:247-257.
16. Palapattu GS, Sutcliffe S, Bastian PJ, Platz1 EA, De Marzo AM, Isaacs WB, Nelson WG: Prostate carcinogenesis and inflammation: emerging insights Carcinogenesis 2004;26:1170-1181.
17. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-412.
18. Yu BP: Aging and oxidative stress: modulation by dietary restriction. Free Radic Biol Med 1996;21:651-668.
19. Aruoma OI, Bahorun T, Clement Y, Mersch-Sundermann V: Inflammation, cellular and redox signaling mechanisms in cancer and degenerative diseases. Mutat Res 2005;579:1-5.
20. Hunt JV, Smith CC, Wolf SP: Autooxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 1991;39:1420-1424.
21. Brownlee M, Vlassara H, Cerami A: Non-enzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984;101:527-537.
22. Yan SD, Schimdt AM, Anderson M, Zhang J, Brett J, Zou YS, Pinsky D, Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994;269:9889-9897.
23. Wolff SP, Dean RT: Glucose autooxidation and protein modification. Biochem J 1987;245:243-250.
24. Wolff SP, Jiang ZY, Hunt JV: Protein glycation and oxidative stress in diabetes mellitus and aging. Free Radic Biol Med 1991;10:339-352.
25. Wells-Knecht MC, Thorps RS, Baynes JW: Pathways of formation of glycoxidation products during glycation of collagen. Biochemistry 1995;34:15134-15141.
26. Green DA, Stevens MJ, Obrosova I, Feldman EL: Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. Eur J Pharmacol 1999;375:217-223.
27. Zochodne DW: Diabetic neuropathies: features and mechanisms. Brain Pathol 1999;9:369-391.
28. Cunningham J, Ellis SL, Mc Veigh KL, Levine RE, Calles-Escandon J: Reduced mononuclear leukocyte ascorbic acid content in adults with insulin dependent diabetes mellitus consuming adequate dietary vitamin C. Metabolism 1991;40:146-149.
29. Yoshida K, Hirokawa J, Tagami S, Kawakami Y, Urata Y, Kondo T: Weakened cellular scavenging activity against oxidative stress in diabetes mellitus: regulation of glutathione synthesis and efflux. Diabetologia 1995;38:201-210.
30. Matsuoka T, Kajimoto Y, Watada H, Kaneto H, Kishimoto M, Umayahara Y, Fujitani Y, Kamada T, Kawamori R, Yamasaki Y: Glycation-dependent, reactive oxygen species mediated suppression of the insulin gene promoter activity in HIT cells. J Clin Invest 1997;99:144-150.
31. Ferrer J, Benito C, Gomis R: Pancreatic islet GLUT 2 glucose transporter mRNA and protein expression in humans with and without NIDDM. Diabetes 1995;44:1369-1374.
32. Pessler D, Rudich A, Bashan N: Oxidative stress impairs nuclear proteins binding to the insulin responsive element in the GLUT4 promoter. Diabetologia 2001;44:2156-2164.
33. Rudich A, Kozlovsky N, Potashnik R, Bahan N: Oxidant stress reduces insulin responsiveness in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 1997;272:E935-E940.
34. Tirosh A, Potashnik R, Bashan N, Rudich A: Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-LI adipocytes. J Biol Chem 1999;274:10595-10602.
35. Lucas MJ, Leveno KJ, Williams ML, Raskin P, Whalley PJ: Early pregnancy glycosylated hemoglobin, severity of diabetes and fetal malformations. Am J Obstet Gynecol 1989;16:426-431.
36. Mills JL, Knopp RH, Simpson JL, Janovic-Peterson L, Metzger BE, Holmes LB, Aarons JH, Brown Z, Reed GF, Bieber FR, Allen MV, Holzman I, Ober C, Peterson CM, Withiam MJ, Duckles A, Mueller-Heubach E, Polk BF: National Institute of child health and human development diabetes in early pregnancy. Lack of relation of increased malformation rates in infants of diabeteic mothers to glycemic control during organogenesis. N Engl J Med 1988;318:671-676.
37. Greene MF: Prevention and diagnosis of congenital anomalies in diabetic pregnancies. Clin Perinatol 1993;20:533-547.
38. Kucera J: Rate and type of congenital anomalies among offspring of diabetic women. J Reprod Med 1971;77:61-70.
39. Mills JL, Baker L, Goldman AS: Malformations in infants of diabetic mothers occur before the seventh gestational week. Diabetes 1979;28:292-293.
40. Eriksson UJ: The pathogenesis of congenital malformations in diabetic pregnancy. Diabetes Metab Rev 1995;11:63-82.
41. Thomas CR, Eriksson GL, Eriksson VJ: Effects of maternal diabetes on placental transfer of glucose in rats. Diabetes 1990;39:276-282.
42. Hagay ZJ, Weiss Y, Zusman I, Peled-Kamar M, Reece EA, Eriksson VJ, Groner Y: Prevention of diabetes associated embryopathy by overexpression of the free radical scavenger copper zinc superoxide dismutase in transgenic mouse embryos. Am J Obstet Gynecol 1995;173:1036-1041.
43. Eriksson UJ, Siman CM: Pregnant diabetic rats fed the antioxidant butylated hydroxytoluene show decreased occurrence of malformations in the offspring. Diabetes 1996;45:1497-1502.
44. Lucas MJ, Leveno KJ, Williams ML, Raskin P, Whalley PJ: Early pregnancy glycosylated hemoglobin, severity of diabetes, and fetal malformations. Am J Obstet Gynecol 1989;16:426-431.
45. Viana M, Herrera E and Bonet BL: Teratogenic effects of diabetes mellitus in the rat: prevention with vitamin E. Diabetologia 1996;39:1041-1046.
46. Sivan E, Reece EA, Wu YK, Homko CJ, Polansky M, Borenstein M: Dietary vitamin E prophylaxis and diabetic embryopathy: morphologic and biochemical analysis. Am J Obstet Gynecol 1996;175:793-799.
47. Siman CM, Eriksson VJ: Vitamin E decreases the occurrence of malformations in the offspring of diabetic rats. Diabetes 1997;46:1054-1061.
48. Kowluru RA, Engerman RL, Case GL, Kern TS: Retinal glutamate in diabetes and effect of antioxidants. Neurochem Intl 2001;38:385-390.
49. Reece AE, Wu YK: Prevention of diabetic embryopathy in offspring of diabetic rats with use of a cocktail of deficient substrates and an antioxidant. Am J Obstet Gynecol 1997;176:790-798.
50. Yang X, Borg LAH, Siman CM, Eriksson VJ: Maternal antioxidant treatments prevent diabetes induced alterations of mitochondrial morphology in rat embryos. Anat Rec 1998;251:303-315.
51. Eriksson UJ, Borg LAH: Protection by free oxygen radical scavenging enzymes against glucose induced embryonic malformations in vitro. Diabetologia 1991;34:325-331.
52. Eriksson VJ, Borg LAH: Diabetes and embryonic malformations: role of substrate induced free oxygen radical production for dysmorphogenesis in cultured rat embryos. Diabetes 1993;42:411-419.
53. Trocino RA, Akazawa S, Ishibashi M, Matsumoto K, Matsuo H, Yamamoto H, Goto S, Urata Y, Kondo T, Nagataki S: Significance of glutathione depletion and oxidative stress in early embryogenesis in glucose-induced rat embryo culture. Diabetes 1995;44:992-998.
54. Wentzel P, Eriksson VJ: Antioxidants diminish developmental damage induced by high glucose and cyclooxygenase inhibitors in rat embryos in vitro. Diabetes 1998;47:677-684.
55. Wentzel P, Thunberg L, Eriksson VJ: Teratogenic effect of diabetic serum is prevented by supplementation of superoxide dismutase and N-acetylcysteine in rat embryo culture. Diabetologia 1997;40:7-14.
56. Goldman AS, Baker L, Piddington R, Marx B, Herold R, Egler J: Hyperglycemia-induced tetratogenesis is mediated by a functional deficiency of arachidonic acid. Proc Natl Acad Sci USA 1985;82:8227-8231.
57. Emerit I: Reactive oxygen species, chromosome mutation, and cancer: possible role of clastogenic factors in carcinogenesis. Free Radic Biol Med 1994;16:99-109.
58. Simmons RA: Developmental origins of diabetes: the role of oxidative stress. Free Radic Biol Med 2006;40:917-922.
59. Young ID: Congenital malformations. Incidence and genetics of congenital malformations; in Brock DJ, Rodeck CH, Ferguson-Smith MA (eds): Prenatal diagnosis and screening. London, Churchill Livingstone, 1992, pp 171-188.
60. Breen AP, Murphy JA: Reaction of oxyl radicals with DNA. Free Radic Biol Med 1995;18:1033-1077.
61. Newcombe TG, Loeb LA: Mechanism of mutagenicity of oxidatively-modified bases;in Aruoma OI, Halliwell B (eds): Molecular Biology of Free Radicals in Human Disease. Saint Lucia, OICA international, 1998, pp 139-166.
62. Aruoma OI, Halliwell B: DNA &Free Radicals: Techniques, Mechanisms and Applications. London, OICA International, 1998.
63. Bucala R, Model P, Cerami A: Modification of DNA by reducing sugars: a possible mechanism for nucleic acid aging and age related dysfunction in gene expression. Proc Natl Acad Sci USA 1984;81:105-109.
64. Lee AT, Plump A, Desimone C, Cerami A, Bucala R: A role for DNA mutations in diabetes associated teratogenesis in transgenic embryos. Diabetes 1995;44:20-24.
65. Eriksson UJ, Wentzel P, Minhas HS and Thornalley PJ: Teratogenicity of 3-deoxyglucosone and diabetic embryopathy. Diabetes 1998;47:1960-1966.
66. Shapiro R, Cohen BI, Shiney SJ, Maurer H: The reaction of guanine with glyoxal, pyruvaldehyde and ketnoxal, and the structure of the acylguanines: a new synthesis of N2-alkylguanines. Biochemistry 1969;8:238-245.
67. Papoulis A, Al-Abed Y, Bucala R: Identification of N2-(1-carboxyethyl) guanine (CEG) as a guanine advanced glycosylation end product. Biochemistry 1995;34:648-655.
68. Okado A, Kawasaki Y, Hasuike Y, Takahashi M, Teshima T, Fujii J, Taniguchi N: Induction of apoptotic cell death by methylglyoxal and 3-deoxyglucosone in macrophage derived cell lines. Biochem Biophys Res Commun 1996;225:219-224.
69. Viana M, Aruoma OI, Herrera E, Bonet B: Oxidative damage in pregnant diabetic rats and their embryos. Free Radic Biol Med 2000;29:1115-1121.
70. Guijarro MV, Indart A, Aruoma OI, Viana M, Bonet B: Effects of ergothioneine on diabetic embryopathy inpregnant rats. Food Chem Toxicol 2002;40:1751-1755.
71. Graziewicz MA, Zastawmy TH, Olinski R, Speina E, Siedlecki J, Tudek B: Fapyadenine is a moderately efficient chain terminator for prokaryotic DNA polymerases. Free Radic Biol Med 2000;28:75-83.
72. Moley KH, Chi MMY, Knudson CM, Korsmeyer SJ, Mueckler MM: Hyperglycemia induces apoptosis in pre-implantation embryos through cell death effector pathways. Nature Med 1998;4:1421-1424.
73. Phelan SA, Ito M, Locken MR: Neural tube defects in embryos of diabetic mice: role of the Pax-3 gene and apoptosis. Diabetes 1997;46:1189-1197.
74. Goulding M, Sterrer S, Fleming J, Balling R, Nadeau J, Moore KJ, Brown SDM, Steel KP, Gruss P: Analysis of the Pax-3 gene in the mouse mutant splotch. Genomics 1993;17:355-363.
75. Auerbach R: Analysis of the developmental effects of a lethal mutation in the house mouse. J Exp Zool 1954;127:305-329.
76. Caprio S, Wong S, Alberti KGMM, King G: Cardiovascular complications of diabetes. Diabetologia 1997;40:B78-B82.
77. Hammes HP: Pathophysiological mechanism of diabetic angiopathy. J Diabetes Complications 2003;17:16-19.
78. Cohen RA: Dysfunction of vascular endothelium in diabetes mellitus. Circulation 1993;87:V67-V76.
79. Pugliese G, Tilton RG, Speedy A, Chang K, Province MA, Kilo C, Williamson JR: Vascular filtration function in galactose-fed versus diabetic rats: the role of polyol pathway activity. Metabolism 1990;39:690-697.
80. Lee TS, Macgregor LC, Fluharty SJ, King GL: Differential regulation of protein kinase C and (Na,K)-adenosine triphosphate activities by elevated glucose levels in retinal capillary endothelial cells. J Clin Invest 1989;83:90-94.
81. Lee TS, Saltsman KA, Ohashi H, King GL: Activation of protein kinase C by elevated glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci USA 1989;86:5141-5145.
82. Craven PA, DeRubertis FR: Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. Possible mediation by glucose. J Clin Invest 1989;83:1667-1675.
83. Craven PA, DeRubertis FR: Sorbinil suppresses glomerular prostaglandin production in the streptozotocin diabetic rat. Metabolism 1989;38:649-654.
84. Greene DA, Lattimer SA, Sima AF: Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987;316:599-606.
85. +, free radicals and vascular dysfunction in early diabetes mellitus. Diabetologia 1997;40:S115-S117.
86. 131I-albumin permeation of retinal and uveal vessels in streptozotocin-diabetic rats. Invest Ophthalmol Vis Sci 1990;31:342.
87. Tesfamariam B, Brown M, Cohen R: Elevated glucose impairs endothelium-dependent relaxation by activated protein kinase C. J Clin Invest 1991;87:1643-1648.
88. Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL: Characterization of the mechanism for the chronic activation of DAG-PKC pathway in diabetes and hypergalactosemia. Diabetes 1994;43:1122-1129.
89. Brownlee M, Pongor S, Cerami A: Covalent attachment of soluble proteins by nonenzymatically glycosylated collagen. J Exp Med 1983;158:1739-1744.
90. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820.
91. Spitaler MM, Graier WF: Vascular targets of redox signaling in diabetes mellitus. Diabetologia 2002;45:476-494.
92. Vlassara H, Brownlee M, Monogue K, Dinarello CA, Pasagian A: Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988;240:1546-1548.
93. Ono H, Umeda F, Sekiguchi N, Inoguchi T, Nawata H: Decrease in insulin binding to aortic endothelial cells cultured with high glucose concentration. Diabet Res Clin Pract 1989;6:115-119.
94. Sekiguchi N, Umeda F, Masakado M, Ono Y, Hashimoto T, Nawata H: Immunohistochemical study of prostacyclin-stimulating factor (PSF) in the diabetic and atherosclerotic human coronary artery. Diabetes 1997;46:1627-1632.
95. Ono Y, Umeda F, Kunisaki M, Sekiguchi N, Hashimoto T, Nawata H: Effect of high glucose concentrations on prostacyclin-stimulating factor mRNA expression in cultured aortic smooth muscle cells. Diabetologia 1998;41:134-140.
96. Lewis MS, Whatleg RE, Cain P, Meintyre TM, Prescott SM, Zimmerman GA: Hydrogen peroxide stimulates the synthesis of platelet-activating factor by endothelium and induces endothelial cell-dependent neutrophil adhesion. J Clin Invest 1988;82:2045-2055.
97. Taniguchi N, Kaneto H, Asahi M, Takahashi M, Wenyi C, Higashiyama S, Fujii J, Suzuki K, Kayanoki Y: Involvement of glycation and oxidative stress in diabetic macroangiopathy. Diabetes 1996;45(suppl 3):S81-S83.
98. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR: Diabetes fibrinogen, and risk of cardiovascular disease: the Fra mingham experience. Am Heart J 1990;120:672-676.
99. Laakso M, Ronnemaa T, Lehto S, Puukka P, Kallio V, Pyorala K: Does NIDDM increase the risk of coronary heart disease similarly in both low- and high-risk populations? Diabetologia 1995;38:487-493.
100. Maher VMG, Browm BG: Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol 1995;6:229-235.
101. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol: modifications of low-density lipoprotein that increases its atherogenicity. N Engl J Med 1989;320:915-924.
102. Kim JA, Berliner JA, Natrajan RD, Nadler JL: Evidence that glucose increases monocyte binding to human aortic endothelial cells. Diabetes 1994;43:1103-1107.
103. van Poppel G, Kardinaal A, Princen H, Kok FJ: Antioxidants and coronary heart disease. Ann Med 1994;26:429-434.
104. Liu YJ, Saini A, Cohen DJ, Ooi BS: Modulation of macrophages proliferation by hyperglycemia. Mol Cell Endocrinol 1995;114:187-192.
105. Saini A, Liu YJ, Cohen DJ, Ooi BS: Hyperglycemia augments macrophage growth responses to colony-stimulating factor-1. Metabolism 1996;45:1125-1129.
106. Sartippour MR, Lambert A, LaFramboise M, St-Jacques P, Renier G: Stimulatory effect of glucose on macrophage lipoprotein lipase expression and production. Diabetes 1998;47:431-438.
107. Bierman EL: George Lyman Duf Memorial Lecture: atherogenesis in diabetes. Arterioscler Thromb 1992;12:647-656.
108. Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathicoadrenal system. N Engl J Med 1996;334:374-381.
109. Mizutani M, Gerhardinger C, Lorenzi M: Müller cell changes in human diabetic retinopathy. Diabetes 1998;47:445-449.
110. Ruderman NB, Williamson JR, Brownlee M: Glucose and diabetic vascular disease. FASEB J 1992;6:2905-2914.
111. Kowluru RA, Tang J, Kern TS: Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 2001;50:1938-1942.
112. Kador PF: The role for aldose reductase in the development of diabetic complications. Med Res Rev 1988;8:325-352.
113. Hammes HP, Brownlee M, Lin J, Schlicher E, Bretzel RG: Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations. Diabetologia 1999;42:603-607.
114. Kowluru RA, Kern TS, Engerman RL, Armstrong D: Abnormalities of retinal metabolism in diabetes or experimental galactosemia. III. Effects of antioxidants. Diabetes 1996;45:1233-1237.
115. Aiello LP, Bursell SE, Clermont A: Vascular endothelial growth factor induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997;46:1473-1480.
116. Bursell SE, Clermont AC, Aiello LP: High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 1999;22:1245-1251.
117. Ellis EA, Grant MB, Murray FT: Increased NADH oxidase activity in the retina of the BBZ/Wor diabetic rat. Free Radic Biol Med 1998;24:111-120.
118. 2, vascular endothelial growth factor and receptors in the retina of the BBZ/Wor diabetic rat. Free Radic Biol Med 2000;28:91-101.
119. Hammes HP, Bartmann A, Engel L, Wulfroth P: Antioxidant treatment of experimental diabetic retinopathy in rats with nicanartine. Diabetologia 1997;40:629-634.
120. Kern TS, Tang J, Mizutani M, Kowluru RA, Nagaraj RH, Romeo G, Podesta F, Lorenzi M: Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest Ophthalmol Vis Sci 2000;41:3972-3978.
121. Shojaee N, Patton WF, Hechtman HB, Shepro D: Myosin translocation in retinal pericytes during free-radical induced apoptosis. J Cell Biochem 1999;75:118-129.
122. Walisser JA, Thies RL: Poly(ADP-ribose) polymerase inhibition in oxidant-stressed endothelial cells prevents oncosis and permits caspase activation and apoptosis. Exp Cell Res 1999;251:401-413.
123. Oka M, Hirouchi M, Itoh Y, Ukai Y: Involvement of peroxynitrite and hydroxyradical generated from nitric oxide in hypoxia/reoxygenation injury in rat cerebrocortical slices. Neuropsychopharmacology 2000;39:1319-1330.
124. Mitzutani M, Kern TS, Lorenzi M: Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1996;97:2883-2890.
125. Podesta E, Romeo G, Liu WH, et al: Bax is increased in the retina of diabetic subjects and is associated with pericyte apoptosis in vivo and in vitro. Am J Pathol 2000;45:59-66.
126. Hebert MJ, Gullans SR, Mackenzie HS, Brady HR: Apoptosis of cells in human and experimental diabetic retinopathy. J Clin Invest 1998;97:2883-2890.
127. Bombeli T, Karsan A, Tait JF, Harlan JM: Apoptotic vascular cells become Procoagulant. Blood 1997;89:2429-2442.
128. Kowluru RA, Kern TS, Engerman RL: Abnormalities of retinal metabolism in diabetes or experimental galactosemia. IV. Antioxidant defense system. Free Radic Biol Med 1997;22:587-592.
129. Kowluru RA, Jirousek MR, Stramm LE, Farid NA, Engerman RL, Kern TS: Abnormalities of retinal metabolism in diabetes or experimental galactosemia. V. Relationship between protein kinase C and ATPases. Diabetes 1998;47:464-469.
130. Leinonen J, Lehtimaki T, Toyokuni S, Okada K, Tanaka T, Hiai H, Ochi H, Laipala P, Rantalaiho V, Wirta O, Pasternack A, Alho H: New biomarker evidence of oxidative DNA damage in patients with non-insulin dependent diabetes mellitus. FEBS Lett 1997;417:150-152.
131. Dandona P, Thusu K, Cook S, Synder B, Makowski J, Armstrong D, Nicotera T: Oxidative damage to DNA in diabetes mellitus. Lancet 1996;347:444-445.
132. Ihara Y, Toyokuni S, Uchida K, Tanaka T, Ikeda H, Hiai H, Seino Y, Yamada Y: Hyperglycemia causes oxidative stress in pancreatic B-cells of GK rats, a model of type 2 diabetes. Diabetes 1999;48:927-932.
133. Soo-Park K, Kim HK, Kim MS, Kim JM, Kim SK, Choi JY, Chung MH, Han B, Kim SY, Lee HK: Effects of insulin and antioxidant on plasma 8-hydroxyguanosine and tissue 8-hydroxydeoxyguanosine in streptozotocin-induced diabetic rats. Diabetes 2001;50:2837-2841.
134. Shin CS, Moon BS, Park KS, Kim SY, Park SJ, Chung MH, Lee HK: Serum 8-hydroxyguanosine levels are increased in diabetic patients. Diabetes Care 2001;24:733-737.
135. 2α levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett 1995;368:225-229.
136. Traverso N, Menini S, Cosso L, Odetti P, Albino E, Pronzato MA and Marinari UM: Immunological evidence for increased oxidative stress in diabetic rats. Diabetologia 1998;41:265-270.
137. Gallou G, Ruelland A, Legras B, Maugendre D, Allannic H, Cloarec L: Plasma MDA in type 1 and type 2 diabetes. Clin Chim Acta 1993;214:227-234.
138. Wierusz-Wysocka B, Wysocki H, Byks H, Zozulinska D, Wicretowiez A, Kazmierczak M: Metabolic control quality and free radical activity in diabetic patients. Diabetes Res Clin Pract 1995;27:193-197.
139. Nourooz Zadeh J, Tajaddini Sarmadi J, Mc Carthy S, Betteridge DJ, Wolff SP: Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 1995;44:1054-1058.
140. Phillips M, Cataneo RN, Cheema T, Greenberg J: Increased breath biomarkers of oxidative stress in diabetes mellitus. Clin Chim Acta 2004:344:189-194.
141. Kaneto H, Kajimoto Y, Miyagawa J, Matsuoka T, Fujitani Y, Umayahara Y, Hanafusa T, Matsuzawa Y, Yamasaki Y, Hori M: Beneficial effects of antioxidants in diabetes: possible protection of pancreatic β-cells against glucose toxicity. Diabetes 1999;48:2398-2406.
142. Kubisch HM, Wang J, Bray TM, Phillips JP: Targeted overexpression of Cu/Zn superoxide dismutase protects pancreatic beta-cells against oxidative stress. Diabetes 1997;46:1563-1566.
143. Evans JL, Goldfine ID: α-Lipoic acid: a multi-functional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. Diabetes Technol Ther 2000;2:401-413.
144. Maddux BA, See W, Lawrence JC, Goldfine AL Jr, Goldfine I, Evans J: Protection against oxidative stress-induced insulin resistance in rat L6 muscle cells by micromolar concentrations of α-lipoic acid. Diabetes 2001;50:404-410.
145. Ziegler D, Reljanovic M, Mehnert H, Gries FA: Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes 1999;107:421-430.
146. Gorogawa S, Kajimoto Y, Umayahara Y, Kaneto H, Watada H, Kuruda A, Kawamori D, Yasuda T, Matsuhisa M, Yamasaki Y, Hori M: Probucol preserves pancreatic β-cell function through reduction of oxidative stress in type 2 diabetes. Diabetes Res Clin Pract 2002;57:1-10.
147. Siman CM, Eriksson VJ: Vitamin C supplementation of the maternal diet reduces the rate of malformation in the offspring of diabetic rats. Diabetologia 1997;40:1416-1424.
148. Yang B, Kotani A, Arai K, Kusu F: Estimation of the antioxidant activities of flavonoids from their oxidation potentials. Anal Sci 2001;17:599-604.
149. Yang CS, Yang GY, Landau JM, Kim S, Liao J: Tea and tea polyphenols inhibit cell hyperproliferation, lung tumorigenesis, and tumor progression. Exp Lung Res 1998;24:629-639.
150. Obrosova IG, Minchenko AG, Marinescu V, Fathallah L, Kennedy A, Stocbert CM, Frank RN, Stevens MJ: Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia 2001;44:1102-1110.
151. Di Leo MA, Ghirlanda G, Gentiloni Silveri N, Giardina B, Franconi F, Santini SA: Potential therapeutic effect of antioxidants in experimental retina: a comparison between taurine and vitamin E plus selenium supplementation. Free Radic Res 2003;37:323-330.
152. Ansari NH, Zhang W, Fulep E, Mansour A: Prevention of pericyte loss by trolox in diabetic rat retina. J Toxicol Environ Health A 1998;54:467-475.
153. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster JR Jr, Williamson JR, Mc Daniel ML: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 1992;41:552-556.
154. File SE, Jarrett N, Fluck E, Duffy R, Casey K, Wiseman H: Eating soya improves human memory. Psychopharmacology 2001;157:430-436.
155. Watanabe CM, Wolffram S, Ader P, Rimbach G, Packer L, Maguire JJ, Schultz PG, Gohil K: The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba. PNAS 2001;98;6577-6580.
156. Wu Y, Wu Z, Butko P, Christen Y, Lambert MP, Klein WL, Link CD, Luo Y: Amyloid-beta-induced pathological behaviors are suppressed by ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 2006;26:13102-13113.
157. Datla KP, Christidou M, Widmer WW, Rooprai HK, Dexter DT: Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in rat model of Parkinson's disease. Neureport 2001;12:3871-3875.
158. Zbarsky V, Datla KP, Parkar S, Rai DK, Aruoma OI, Dexter DT: Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radic Res 2005;39:1119-1125.
159. Tebib K, Bitri L, Besancon P, Rouanet JM: Polymeric grape seed tannins prevent plasma cholesterol changes in high-cholesterolfed rats. Food Chem 1994;49:403-406.
160. Yen GC, Chen HY: Antioxidant activity of various tea extracts in relation to their antimutagenicity. J Agric Food Chem 1995;43:27-32.
161. Liviero L, Puglisi PP, Bombardelli E: Antimutagenic activity of procyanidins from Vitis vinifera. Fitoterapia 1994;65:203-209.
162. Horn R, Vondermuhll M, Comte M, Grandroques C: Action de quelques catechins sur l'activitéd'un enzyme (la cytochrome oxidase) de la chaine respiratoire. Experiential 1970:26:1081-1082.
163. Hertog MGL, Fesken E, Hollman P, Katan M, Kromhout D: Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly study. Lancet 1993;342:1007-1010.
164. Teissedre P, Frankel EN, Waterhouse AL, Peleg H, German JB: Inhibition of in vitro human LDL oxidation by phenolic oxidants from grapes and wines. J Sci Food Agric 1996;70:55-61.
165. Bagchi D, Sen CK, Ray SD, Das DK, Bagchi M, Preuss HG, Vinson JA: Molecular mechanisms of cardioprotection by a novel grape seed proanthocyanidin extract. Mutat Res 2003;523-524:87-97.
166. Yamakoshi J, Saito M, Kataoka S, Tokutake S: Procyanidin-rich extract from grape seeds prevents cataract formation in hereditary cataractous (ICR/f) rats. J Agric Food Chem 2002;50:4983-4988.
167. De Martinis M, Franceschi C, Monti D, Ginaldi L: Inflammation markers predicting frailty and mortality in the elderly. Exp Mol Pathol 2006;80:219-227.
168. Arai H, Furuya T, Mizuno Y, Mochizuki H: Inflammation and infection in Parkinson's disease. Histol Histopathol 2006;21:673-678.
169. Aruoma OI, Sun B, Fujii H, Vidushi S, Neergheen VS, Bahorun T, Kang KS, Sung MK: Low molecular proanthocyanidin dietary biofactor Oligonol: its modulation of oxidative stress, bioefficacy, neuroprotection, food application and chemoprevention potentials. Biofactors 2006;27:245-265.
170. Hertog MGL, Kromhout D, Aravanis C: Flavonoid intake and log-term risk of coronary heart disease and cancer in seven countries study. Arch Intern Med 1995;155:381-386.
171. Salah N;Miller NG, Paganga G, Tigburg L, Bolwell GP, Rice-Evans C: Polyphenolic flavonoids as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Arch Biochem Biophys 1995;322:339-346.
172. Maeda K, Kuzuya M, Cheng X, Asai T, Kanda S, Tamaya-Mori N, Sasaki T, Shibata T, Iguchi A: Green tea catechins inhibit the cultured smooth muscle cell invasion through the basement barrier. Atherosclerosis 2003;166:23-30.
173. Bahorun T, Trotin F, Pommery J, Vasseur J, Pinkas M: Antioxidant activities of Crataegus monogyna extracts. Planta Med 1994;60:323-328.
174. Schüssler M, Hölzl J, Fricke U: Myocardial effects of flavonoids from Crataegus species. Arzneimittelforschung 1995;45:842-845.
175. Xu R, Yokoyama WH, Irving D, Rein D, Walzem RL, German JB: Effect of dietary catechin and vitamin E on aortic fatty streak accumulation in hypercholesterolemic hamsters. Atherosclerosis 1998;137:29-36.
176. Belinky PA, Aviram M, Fuhrman B, Rosenblat M, Vaya J: The antioxidative effects of the isoflavan glabridin on endogenous constituents of LDL during its oxidation. Atherosclerosis 1998;137:49-61.
177. Renaud S, Lorgeril M: Wine, alcohol, platelets and the French paradox for coronary heart disease. Lancet 1992;339:1523-1526.
178. Criqui MH, Ringel BL: Does diet or alcohol explain the French Paradox? Lancet 1994;344:1719-1723.
179. Belleville J: The French Paradox: possible involvement of ethanol in the protective effect against cardiovascular disease. Nutrition 2002;18:173-177.
180. Kaur G, Roberti M, Raul F, Pendurthi UR: Suppression of human monocyte tissue factor induction by red wine phenolics and synthetic derivatives of resveratrol. Thromb Res 2007;119:247-256.
181. Zern TL, Fernandez ML: Cardioprotective effects of dietary polyphenols. J Nutr 2005;135:2291-2294.
182. Vedavanam K, Srijayanta S, O'Reilly J, Raman A, Wiseman H: Antioxidant action and potential antidiabetic properties of an isoflavonoid-containing soyabean phytochemical extract (SPE). Phytother Res 1999;13:601-608.
183. Hermansen K, Sondergaard M, Hoie L, Carstensen M, Brock B: Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects. Diabetes Care 2001;24:228-233.
184. Vinson JA, Zhang J: Black and green teas equally inhibit diabetic cataracts in a streptozotocin-induced rat model of diabetes. J Agric Food Chem 2005;53:3710-3713.
185. Wolfram S, Raederstorff P, Preller M, Wang Y, Teixeira SR, Riegger C, Weber P: Epigallocatechin gallate supplementation alleviates diabetes in rodents. J Nutr 2006;136:2512-2518.
186. Rodriguez de Sotillo DV, Hadley M: Chlorogenic acid modifies plasma and liver concentrations of: cholesterol, triacylglycerol, and minerals in (fa/fa) Zucker rats. J Nut Biochem 2002;13:717-726.
187. Balasubashini MS, Rukhumani R, Viswanathan P, Menon VP: Ferulic acid alleviates lipid peroxidation in diabetic rats. Phytother Res 2004;18:310-314.
188. Jayaprakasam B, Vereed SK, Olson LK, Nair MG: Insulin secretion by bioactive anthocyanins and anthocyanidins present in fruits. J Agric Food Chem 2005;53:28-31.
189. Aring, AM, Jones DE, Falko JM: Evaluation and prevention of diabetic neuropathy. Am Fam Physician 2005;71:2123-2128.
190. Aring AM, Jones DE, Falko JM: Evaluation and prevention of diabetic neuropathy: Patient information on neuropathy. Am Fam Physician 2005;71:2129-2130.
191. Feldman EL, Russell JW, Sullivan KA, Golovoy D: New insights into the pathogenesis of diabetes neuropathy. Curr Opin Neurol 1999;12:553-563.
192. Brown MJ, Asbury AK: Diabetic neuropathy. Ann Neurol 1984;15:2-12.
193. Melton JL III, Dyck PJ: Clinical features of the diabetic neuropathies;in Dyck PJ, Thomas PK, Asbury AK, Winegrad AI, Porte D Jr (eds): Diabetic Neuropathy. Philadelphia, WB Saunders, 1987, pp 27-35.
194. American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 2005;28(suppl 1):S4-S36.
195. Vinik AI, Holland MT, Le Beau JM, Liuzzi FJ, Stansberry KB, Colen LB: Diabetic neuropathies. Diabetes Care 1992;15:1926-1975.
196. Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA: Diabetic neuropathy: an intensive review. Am J Health-Syst Pharm 2004;61:160-173.
197. May O, Arildsen H: Assessing cardiovascular autonomic neuropathy in diabetes mellitus: how many tests to use? J Diabetes Complications 2000;14:7-12.
198. Palumbo PJ, Elveback LR, Whisnant JP: Neurologic complications of diabetes mellitus: transient ischemic attack, stroke, and peripheral neuropathy. Adv Neurol 1978;19:593-601.
199. Vinik AI, Maser RE, Mitchell BD, Freeman R: Diabetic autonomic neuropathy. Diabetes Care 2003;26:1553-1579.
200. Olaleye D, Perkins BA, Bril V: Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic. Diabetes Res Clin Pract 2001;54:115-128.
201. Frykberg RG, Armstrong DG, Giurini J, Edwards A, Kravette M, Kravitz S, Ross C, Stavosky J, Stuck R, Vanore J: Diabetic foot disorders: a clinical practice guideline. American College of Foot and Ankle Surgeons. J Foot Ankle Surg 2000;39(5 suppl):S1-S60.
202. Jones MC, Patel M: Insulin detemir: a long-acting insulin product. Am J Health-Syst Pharm 2006;63:2466-2472.
203. Obrosova IG: How does glucose generate oxidative stress in peripheral nerve? Int Rev Neurobiol 2002;50:3-35.
204. Bullano MF, Fisher MD, Grochulski WD, Menditto L, Willey VJ: Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products. Am J Health Syst Pharm 2006;63:24734-24782.
205. Pop-Busui R, Sullivan KA, Van Huysen C, Bayer L, Cao X, Towns R, Stevens MJ: Depletion of taurine in experimental diabetic neuropathy: implications for nerve, metabolic, vascular, and functional deficits. Exp Neurol 2001;168:259-272.
206. Van Dam PS, Bravenboer B, van Asbeck BS, Joannes JM, Marx JJM, Gispen WHG: High rat food vitamin E content improves nerve function in streptozotocin-diabetic rats. Eur J Pharmacol 1999;376:217-222.
207. Kumar A, Kaundal KK, Iyer S, Sharma SS: Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sci 2007;80:1236-1244.
208. Chandra A, Mahdi AA, Sohail Ahmad S, Singh RK: Indian herbs result in hypo-glycemic responses in streptozotocin-induced diabetic rats. Nutr Res 2007;27:161-168.
209. Li F, Abatan OI, Kim H, Burnett D, Larkin D, Obrosova IG, Stevens MJ: Taurine reverses neurological and neurovascular deficits in Zucker diabetic fatty rats. Neurobiol Dis 2006;22:669-676.
210. Pacher P, Szabo C: Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr Opin Pharmacol 2006;6:136-141.
211. Pasantes-Morales H, Martin DL, Shain W, del Rio RM: Taurine: functional neurochemistry, physiology and cardiology. Prog Clin Biol Res 1990;351:1-488.
212. Aruoma OI, Halliwell B, Hoey BM, Butler J: The antioxidant action of taurine, hypotaurine and their metabolic precursors. Biochem J 1988;256:251-255.
213. Alarcan-Aguilara FJ, Roman-Ramas R, Peret-Gutierrez S, Aguilar-Contreras JL: Study of the anti-hyperglycemic effect of plants used as antidiabetics. J Ethnopharmacol 1998;61:101-110.
214. Coimbra TC, Danni FG, Blotta RM, Da Periara CA, Guedes MD, Graf RG: Plants employed in the treatment of diabetes mellitus. Results of an ethanopharmacological survey in Porto Alegre, Brazil. Fitoterapia 1992;63:320-322.
215. Bradharst CL, Polansky MM, Anderson RA: Insulin like biological activity of culinary and medicinal plant aqueous extraction in vitro. J Agri Food Chem 2000;48:849-852.
216. Grover JK, Yadav SF, Vats V: Medicinal plants of India with anti-diabetic potential. J Ethanopharmacol 2002;81:81-100.
217. Roman-Ramos R, Flores-Saenz JL, Alarcan-Aguilar FJ: Anti-hypoglycemic effect of some of edible plants. J Ethanopharmacol 1995;48:25-32.
218. American Diabetes Association: Nephropathy in diabetes. Diabetes Care 2004;27(suppl 1):S79-S83.
219. DeForonzo RA: Diabetic nephropathy: etiologic and therapeutic considerations. Diabetes Rev 1995;3:510-564.
220. Harvey JN: Diabetic nephropathy. New drugs can help to face a growing challenge. BMJ 2002;325:59-60.
221. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
222. The Microalbuminuria Captopril Study Group: Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996;39:587 -593.
223. Tomohiro T, Kumai T, Sato T, Takeba Y, Kobayashi S, Kimura K: Hypertension aggravates glomerular dysfunction with oxidative stress in a rat model of diabetic nephropathy. Life Sci 2007;80:1364-1372.
224. Wu Y-G, Lin H, Qi X-M, Wu G-Z, Qian H, Zhao M, Shen J-J, Lin S-T: Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes. Int Immunopharmacol 2006;6:445-453.
225. Dursun E, Timur M, Dursun B, Süleymanlar G, Ozben T: Protein oxidation in Type 2 diabetic patients on hemodialysis. J Diabetes Complications 2005;19:142-146.
226. Al-Azzawie HF, Alhamdani MS: Hypoglycemic and antioxidant effect of oleuropein in alloxan-diabetic rabbits. Life Sci 2006;78:1371-1377.
227. Aruoma OI, Deiana M, Jenner A, Halliwell B, Kaur H, Banni S, Corongiu FP, Dessi AM, Aeschbach R: Effect of hydroxytyrosol on oxidative DNA damage and on low density lipoprotein oxidation in vitro. J Agric Food Chem 1998;46:5181-5187.
228. Deiana M, Aruoma OI, Bianchi MLP, Spencer JPE, Kaur H, Halliwell B, Aeschbach R, Banni S, Dessi AM, Corongiu FP: Inhibition of peroxynitrite dependent DNA base modification and tyrosine nitration by the olive oil-derived antioxidant hydroxytyrosol. Free Radic Biol Med 1999;26:762-769.
229. Obrosova IG, Fathallah L, Liu E, Nourooz-Zadeh J: Early oxidative stress in the diabetic kidney: effect of DL-α-lipoic acid. Free Radic Biol Med 2003;34:186-195.
230. Taguchi T, Miyoshi H, Sugiura M, Takeuchi M, Yanagisawa K, Watanabe Y, Miwa I, Makita Z: A glycation inhibitor, aminoguanidine and pyridoxal adduct, suppresses the development of diabetic nephropathy. Int Congr Ser 2002;1245:435-437.
231. Stefek M, Tribulova N, Gajdosik A, Gajdosikova A: The pyridoindole antioxidant stobadine attenuates histochemical changes in kidney of streptozotocin-induced diabetic rats. Acta Histochem 2002;104:413-441.